From Pathways to PROs: Translating the Latest Evidence for Current and Emerging JAK Inhibitors to Clinical Practice
Premiere Date: Tuesday, November 20, 2018This activity offers CE credit for:
- Physicians (CME)
- Nurses (CNE)
- Pharmacists (ACPE)
- ABIM (MOC)
- Other
All other clinicians will receive a Certificate of Attendance stating this activity was certified for AMA PRA Category 1 Credit™
Credit Expiration Date:
Wednesday, November 20, 2019
Note: Credit Is No Longer Available
 | Stanley B. Cohen, MD Clinical Professor, Department of Internal Medicine University of Texas Southwestern Medical School Co-Director, Division of Rheumatology Presbyterian Hospital, Dallas Co-Medical Director Metroplex Clinical Research Center Dallas, TX Past President of the American College of Rheumatology Atlanta, GA |
 | Leonard H. Calabrese, DO Professor of Medicine Vice Chair, Department of Rheumatic & Immunologic Disease Cleveland Clinic Lerner College of Medicine of Case Western Reserve University R.J. Fasenmyer Chair of Clinical Immunology Cleveland Clinic Foundation Cleveland, OH |
Current therapeutic approaches for RA rely on disease-modifying antirheumatic drugs (DMARDs) as well as on biologic therapeutics that target tumor necrosis factor (TNF), interleukin-6 (IL-6), and T cell activation or that eliminate CD20+ B cells. These treatments have limitations, such as waning efficacy over time, side effects, and dosing inconvenience. Clinicians need to be aware of what other treatment options exist or are emerging. Further, rheumatology clinicians often face challenges in translating clinical evidence and data to real-world practice, and assessing the role of patient-reported outcomes (PROs) is pertinent when determining the value of new therapeutics for RA.
This CME Outfitters enduring material, featuring expert faculty discussion and learner interactivity, will address gaps related to emerging discoveries of inflammatory targets, clinical trial data, and the role of patient-reported outcomes (PROs) in practice, with resources posted to the Rheumatology Digital Hub.
At the end of this CE activity, participants should be able to:
- Translate basic clinical immunology to current evidence for the pathophysiology and MOA for current and emerging JAK inhibitors.
- Evaluate clinical trial data for emerging small molecule/intracellular signaling targets in the management of patients with rheumatoid arthritis.
- Assess the role of patient-reported outcomes (PROs) as measures for the value of new therapeutics for RA, in addition to safety and efficacy data.
The following learning objectives pertain only to those requesting CNE or CPE credit:
- Translate basic clinical immunology to current evidence for the pathophysiology and MOA for current and emerging JAK inhibitors.
- Evaluate clinical trial data for emerging small molecule/intracellular signaling targets in the management of patients with rheumatoid arthritis (RA).
- Assess the role of patient-reported outcomes (PROs) as measures for the value of new therapeutics for RA, in addition to safety and efficacy data.
Supported by an educational grant from Gilead Sciences, Inc.
Rheumatologists, primary care physicians, nurse practitioners, physician assistants, nurses, and pharmacists who treat patients with rheumatoid arthritis.
CME Credit (Physicians):
CME Outfitters, LLC is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.
CME Outfitters, LLC, designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
AAPA Credit (Physician Assistants):
NACCME has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with the AAPA CME Criteria. This activity is designated for 1.0 AAPA Category 1 credit. PAs should only claim credit commensurate with the extent of their participation.
CNE Credit (Nurses):
Provider approved by the California Board of Registered Nursing, Provider Number CEP 15510, for 1.5 contact hours
Note to Nurse Practitioners: Nurse practitioners can apply for AMA PRA Category 1 Credit(s)TM through the American Academy of Nurse Practitioners (AANP). AANP will accept AMA PRA Category 1 Credit(s)TM from organizations accredited by the Accreditation Council for Continuing Medical Education. Nurse practitioners can also apply for credit through their state boards.
CPE Credit (Pharmacists):
CME Outfitters, LLC, is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. 1.5 contact hours (0.15 CEUs) Universal Activity Number:
Enduring: 0376-0000-18-020-H01-P
Type: knowledge-based
ABIM MOC Credit:
Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.5 MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
Learning Formats:
Live activity
Enduring Material
MIPS Improvement Activity: This activity counts towards MIPS Improvement Activity requirements under the Medicare Access and CHIP Reauthorization Act of 2015 (MACRA). Clinicians should submit their improvement activities by attestation via the CMS Quality Payment Program website.
Note to Physician Assistants: AAPA accepts certificates of participation for educational activities certified for AMA PRA Category 1 Credit(s)TM from organizations accredited by the Accreditation Council for Continuing Medical Education.
Post-tests, credit request forms, and activity evaluations must be completed online at www.cmeoutfitters.com/TST28452 (requires free account activation), and participants can print their certificate or statement of credit immediately (75% pass rate required). This website supports all browsers except Internet Explorer for Mac. For complete technical requirements and privacy policy, visit www.neurosciencecme.com/technical.asp
Disclosure Declaration
It is the policy of CME Outfitters, LLC, to ensure independence, balance, objectivity, and scientific rigor and integrity in all of their CE activities. Faculty must disclose to the participants any relationships with commercial companies whose products or devices may be mentioned in faculty presentations, or with the commercial supporter of this CE activity. CME Outfitters, LLC, has evaluated, identified, and attempted to resolve any potential conflicts of interest through a rigorous content validation procedure, use of evidence-based data/research, and a multidisciplinary peer review process. The following information is for participant information only. It is not assumed that these relationships will have a negative impact on the presentations.
Dr. Cohen reports that he is a clinical investigator and/or research consultant for AbbVie Inc.; AstraZeneca; Biogen Idec Inc.; Bristol-Myers Squibb Company; Genentech, Inc.; Janssen Pharmaceuticals, Inc.; Eli Lilly and Company; Novartis Pharmaceuticals Corporation; Pfizer Inc.; Merck & Co., Inc.; F. Hoffmann-La Roche Ltd.
Dr. Calabrese reports that he is a consultant for AbbVie Inc.; Centocor Biopharmaceutical; Crescendo Bioscience, Inc.; GlaxoSmithKline; Horizon Pharma; Janssen Pharmaceuticals, Inc.; Pfizer Inc.; Regeneron Pharmaceuticals, Inc.; UCB, Inc.
Kate Nelson, PHD (planning committee) has no disclosures to report.
Sharon Tordoff(planning committee) has no disclosures to report.
Jan Perez (planning committee) has no disclosures to report.
Jeffrey Helfand, DO, MS (peer reviewer) has no disclosures to report.
Mae Ochoa, RPh (peer reviewer) has no disclosures to report.
Disclosures were obtained from the CME Outfitters, LLC staff: No disclosures to report.
Faculty of this CE activity may include discussions of products or devices that are not currently labeled for use by the FDA. The faculty have been informed of their responsibility to disclose to the audience if they will be discussing off-label or investigational uses (any uses not approved by the FDA) of products or devices.
Questions about this activity? Call us at 877.CME.PROS (877.263.7767).
MMV-085-112318-47
